White Paper for Peak Body Ltd.

Authored by: Dr. Richard Fox PhD
Chief Scientific Officer: DioMEDe Sciences

The Physicochemical and Pharmacological Imperative of SNAC-Enabled Gastric Absorption for Oral Semaglutide: A Comprehensive Analysis of Tablet Formulation Necessity and Clinical Non-Inferiority to Injectable Formulations

Abstract

The advent of oral semaglutide represents a watershed moment in pharmaceutical development, marking the first time a glucagon-like peptide-1 receptor agonist (GLP-1 RA) has been successfully delivered via the oral route for the treatment of Type 2 Diabetes Mellitus (T2DM) and weight management. Historically, the oral delivery of peptides has been thwarted by the harsh proteolytic environment of the gastrointestinal (GI) tract and the impermeability of the intestinal epithelium. This report provides an exhaustive analysis of the Eligen® technology, specifically the carrier molecule sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), and articulates why a co-formulated tablet designed for gastric erosion is strictly necessary over enteric-coated capsules. The analysis demonstrates that the mechanism of SNAC is highly localized, requiring high concentrations to neutralize gastric pepsin and fluidize the epithelial membrane—conditions achievable only through the erosion of a tablet in the stomach. Conversely, enteric-coated capsules release their payload in the small intestine, where dilution and the activity of trypsin and chymotrypsin render the SNAC technology ineffective. Furthermore, this report synthesizes extensive data from the PIONEER clinical trial program to validate that this novel delivery system achieves therapeutic non-inferiority, and in some cases superiority, regarding weight loss compared to established injectable therapies.

1. Introduction: The Historical Challenge of Oral Peptide Delivery

The therapeutic potential of peptides and proteins is vast, offering high specificity and potency for targets that small molecules cannot reach. However, since the discovery of insulin in 1921, the pharmaceutical industry has faced a century-long struggle to deliver these macromolecules orally.[1] The oral route is universally preferred by patients due to ease of use, non-invasiveness, and higher adherence rates compared to parenteral (injectable) administration. Yet, the bioavailability of orally administered peptides typically falls below 1%, often rendering them therapeutically irrelevant.[3]

1.1 The Intrinsic Vulnerability of GLP-1

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by the L-cells of the intestine. It regulates glucose homeostasis by stimulating insulin secretion, suppressing glucagon, and delaying gastric emptying. Native GLP-1 is degraded within minutes by the enzyme dipeptidyl peptidase-4 (DPP-4) and rapidly cleared by the kidneys.[5] While synthetic

analogues like semaglutide have been engineered for resistance to DPP-4 (via Aib substitution at position 8) and extended half-life (via C18 fatty acid acylation for albumin binding) [6], these structural modifications do not confer immunity to the hostile environment of the digestive tract.

1.2 The "Capsule vs. Tablet" Dichotomy

A central theme of this report is the distinction between formulation strategies. The "standard" approach for protecting acid-labile drugs is the enteric-coated capsule, which resists stomach acid and releases the drug in the neutral environment of the small intestine. For decades, this was assumed to be the path forward for oral peptides. However, the development of oral semaglutide (Rybelsus®) defied this convention by utilizing a tablet designed to erode specifically in the stomach.[2] Understanding why the "intestine-targeting capsule" fails and the "stomach-targeting tablet" succeeds requires a granular examination of GI enzymology, membrane biophysics, and the unique pharmacokinetic properties of the absorption enhancer SNAC.

2. The Gastrointestinal Gauntlet: Physiochemical Barriers to Absorption

To comprehend the necessity of the SNAC-tablet formulation, one must first dissect the formidable barriers the human gastrointestinal tract presents to a molecule like semaglutide, which has a molecular weight of approximately 4,113 Daltons.[1]

2.1 The pH Gradient and Acid Hydrolysis

The human stomach maintains a fasting pH of approximately 1.0 to 2.0.[8] This acidity is a primary defense mechanism against pathogens and a chemical tool for denaturing dietary proteins. For therapeutic peptides, exposure to this environment can lead to irreversible conformational changes, precipitation, and acid hydrolysis of peptide bonds. While semaglutide is chemically robust compared to native GLP-1, it remains susceptible to pH-induced denaturation, which exposes its internal structure to proteolytic enzymes.[8]

However, the pH barrier is not merely about acid damage; it regulates enzymatic activity. The stomach's primary protease, pepsin, is activated solely in acidic conditions. As the chyme moves into the duodenum, the pH rises to 5.5–7.0, and eventually to 7.0–7.5 in the ileum.[8] This pH gradient dictates which proteolytic enzymes are active in each segment of the GI tract, a variable that is critical to the formulation strategy.

2.2 The Enzymatic Barrier: The Pepsin vs. Pancreatic Dichotomy

A crucial insight derived from the failure of enteric-coated capsules is the differential enzymatic profile of the stomach versus the small intestine.

- **Gastric Proteolysis (The Pepsin Threat):** The stomach secretes pepsinogen, which autocatalytically converts to pepsin in the presence of acid. Pepsin preferentially cleaves peptide bonds at the C-terminal side of hydrophobic and aromatic amino acids (phenylalanine, tryptophan, tyrosine).[8] Crucially, pepsin has a strict pH dependency; it is maximally active at pH 2.0 and loses significant activity above pH 4.5, becoming

irreversibly inactive at pH > 7.0.[8]

- **Intestinal Proteolysis (The Pancreatic Threat):** Upon entering the small intestine, peptides encounter a "kill zone" of pancreatic proteases, including trypsin, chymotrypsin, and elastase.[9]
  - **Trypsin:** Cleaves at the carboxyl side of lysine and arginine.
  - **Chymotrypsin:** Targets large hydrophobic residues.
  - **Activity Profile:** Unlike pepsin, these enzymes function optimally at neutral to alkaline pH (6.0–8.0). This is the exact pH range targeted by enteric-coated delivery systems. Consequently, a capsule that bypasses the stomach delivers the peptide directly into the milieu where proteolytic activity is most diverse and aggressive.[8]

2.3 The Permeability Barrier: Lipophilicity and Pore Size

The intestinal epithelium consists of a phospholipid bilayer that acts as a gatekeeper, allowing the passage of lipophilic small molecules while excluding large, hydrophilic molecules like peptides.

- **Paracellular Route:** Transport between cells is governed by tight junctions (zonula occludens). These junctions generally restrict the passage of molecules larger than 500 Da (or 0.5 kDa).[3] Semaglutide, at ~4.1 kDa, is too large to pass through these junctions passively.
- **Transcellular Route:** Transport *through* the cell requires the molecule to partition into the lipid membrane, traverse the cytosol, and exit the basolateral membrane. Peptides are typically polar and hydrophilic, making them incompatible with the lipophilic membrane environment.[8]

Standard permeation enhancers often target the paracellular route by disrupting tight junctions (e.g., EDTA, Sodium Caprate in some contexts). However, this approach risks allowing the influx of toxins and pathogens. The SNAC technology takes a fundamentally different approach by targeting the transcellular route in the stomach, a distinction that necessitates the tablet formulation.

3. The Solution: Eligen® Technology and SNAC Chemistry

The breakthrough for oral semaglutide was the co-formulation with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), a carrier molecule derived from salicylic acid.[2] SNAC is not a standard excipient; it is an active pharmaceutical ingredient in its own right that transiently modifies the biological environment to permit absorption.

3.1 Chemical Structure and Properties of SNAC

SNAC is a small fatty acid derivative (molecular weight ~300 Da) possessing both a lipophilic octyl chain and a hydrophilic terminal carboxylate group.[12] This amphiphilic structure allows SNAC to interact with both the aqueous gastric fluid and the lipid membranes of epithelial cells. It has been granted Generally Recognized As Safe (GRAS) status by the FDA, highlighting its safety profile compared to other permeation enhancers that may permanently damage tissue.[3]

3.2 Mechanism 1: Local pH Buffering (Pepsin Inactivation)

The primary reason SNAC is effective in the stomach—and why the tablet formulation is required—is its buffering capacity.

- **The Mechanism:** Upon dissolution of the tablet in the stomach, SNAC releases localized alkalinity. It acts as a buffer, neutralizing the protons (H+) in the immediate microenvironment surrounding the tablet.[6]
- **The Consequence:** This local neutralization raises the pH of the gastric fluid immediately adjacent to the tablet to approximately 5.5 or higher. Since pepsin requires acidic pH for activity, this pH elevation effectively inactivates pepsin in the absorption zone.[2] This creates a transient "protective shield" around the semaglutide molecules as they are released, preventing gastric degradation.
- **Contrast with Intestine:** In the small intestine, the pH is already near-neutral (6.0–7.4). Therefore, the buffering capacity of SNAC provides no additional benefit against intestinal proteases like trypsin and chymotrypsin, which are fully active at neutral pH.[8]

3.3 Mechanism 2: Promotion of Monomerization

Semaglutide, like many lipidated peptides, has a tendency to self-associate into large oligomers (multimers) in solution due to hydrophobic interactions between the C18 fatty acid chains.[6] These oligomers are sterically hindered and diffuse poorly across membranes.

- **The SNAC Effect:** SNAC interacts non-covalently with the semaglutide peptide backbone and its lipid tail. This interaction weakens the intermolecular forces holding the oligomers together, effectively forcing the peptide to dissociate into monomers.[2]
- **Relevance:** Monomeric semaglutide is smaller and possesses a polarity profile that is more amenable to interaction with the cell membrane. This monomerization effect is highly specific; studies comparing liraglutide with SNAC showed lower bioavailability partly because liraglutide aggregates more strongly, and SNAC is less efficient at monomerizing it compared to semaglutide.[6]

3.4 Mechanism 3: Transcellular Membrane Fluidization

Perhaps the most sophisticated aspect of the SNAC mechanism is its ability to facilitate transcellular flux.

- **Membrane Interaction:** Molecular dynamics simulations and in vitro studies suggest that SNAC molecules insert themselves into the phospholipid bilayer of the gastric epithelial cells.[10]
- **The "Quicksand" Effect:** By embedding in the membrane, SNAC disrupts the packing of the lipid tails, increasing membrane fluidity. This creates transient, fluid-filled defects or channels—described in biophysical literature as a "quicksand" effect—that allow the hydrophilic semaglutide monomer to slip through the lipophilic barrier.[6]
- **Reversibility:** Critically, this membrane perturbation is transient. As the concentration of SNAC dissipates (due to dilution or absorption), the lipid bilayer re-anneals, and membrane integrity is restored within minutes. This reversibility is key to the safety profile of Rybelsus, distinguishing it from surfactants that strip away the epithelium.[6]

4. Formulation Mechanics: The Tablet Imperative vs. The Capsule Fallacy

Why the capsule form fails (is destroyed) while the tablet succeeds. The answer is rooted in the principles of **Co-Release**, **Local Concentration**, and **Site-Specific Absorption**.

4.1 The Failure of Enteric-Coated Capsules

The logic of using an enteric-coated capsule is to protect the peptide from stomach acid. However, for the specific combination of Semaglutide and SNAC, this strategy is chemically and pharmacokinetically flawed.

1. **The Dilution Problem:** SNAC functions via a *concentration-dependent* mechanism. It requires a massive molar excess relative to the peptide (300 mg SNAC vs. 3–14 mg semaglutide) to create the pH buffer zone and the membrane defects.[15]
    - **In the Intestine:** When an enteric-coated capsule dissolves in the small intestine, it releases its contents into a relatively large volume of intestinal fluid. The peristaltic movement and high fluid turnover rapidly dilute the SNAC. The concentration drops below the critical threshold required to fluidize the membrane or shield the peptide.[17]
2. **The "Kill Zone" of Proteases:** As established in Section 2.2, the small intestine is rich in trypsin and chymotrypsin. These enzymes are active at neutral pH. The buffering action of SNAC is irrelevant here because the environment is already neutral. Therefore, releasing semaglutide in the intestine exposes it to rapid degradation by enzymes that SNAC cannot inhibit.[8]
3. **Separation of Enhancer and Drug:** Capsules often dissolve in a way that allows the excipient and the drug to separate before reaching the epithelial wall. If SNAC is absorbed or diluted before the semaglutide reaches the membrane, the "door" is closed, and the peptide is washed away.[16]

4.2 The Success of the Gastric-Retentive Tablet

The Rybelsus formulation is an erosion-based tablet engineered for **Complete Tablet Erosion (CTE)** in the stomach.[2]

- **Erosion and Concentration:** The tablet is designed to sink to the antrum (lower stomach) and erode gradually. This erosion creates a boundary layer of *extremely high concentration* of SNAC right next to the gastric mucosa. In this microscopic layer, the pH is raised to >5.5 (inactivating pepsin), and the membrane is fluidized.[2]
- **Co-Localization:** Because the semaglutide is embedded in the same matrix as the SNAC, they are released simultaneously and spatially co-localized. The semaglutide is released *directly into* the protective SNAC cloud, ensuring it is protected from acid and pepsin while simultaneously being presented to the fluidized membrane.[6]
- **Gastric Absorption Site:** Pharmacoscintigraphy (gamma camera) studies in humans have confirmed that absorption occurs primarily in the stomach.
    - **Data Point:** Slower tablet erosion correlates with higher plasma exposure (AUC), indicating that prolonged residence in the stomach maximizes the absorption window.[7]
    - **Animal Data:** In dogs with pyloric ligation (blocking passage to the intestine), plasma levels of semaglutide were similar to non-ligated dogs, proving that intestinal entry is *not* required for absorption and that the stomach is the primary site of uptake.[2]

4.3 Summary Comparison: Tablet vs. Capsule

Feature	SNAC Tablet Formulation (Rybelsus)	Enteric-Coated Capsule
Target Release Site	Stomach (Gastric Antrum)	Small Intestine (Duodenum/Jejunum)
Local Fluid Volume	Low (if taken with 120ml water)	High (intestinal secretions + chyme)
SNAC Concentration	Very High (localized at erosion site)	Low (rapidly diluted by fluid)
Enzymatic Threat	Pepsin (Acid-dependent)	Trypsin/Chymotrypsin (Neutral active)
Protection Mechanism	Local buffering raises pH >5.5, inactivating pepsin.	None; neutral pH supports protease activity.
Membrane Transport	Transcellular (SNAC-induced defects in gastric mucosa).	Restricted by tight junctions and mucus; SNAC too diluted to work.
Outcome	**Bioavailable (~1%)**	**Degraded & Excreted (Bioavailability ~0%)**

5. Pharmacokinetics: Bioavailability and Administration Rigor

The success of the tablet formulation yields an oral bioavailability of approximately 0.4% to 1.0%.[3] While this percentage appears low compared to small molecules (often >90%), the extreme potency of semaglutide and its long half-life (~1 week) allow this fraction to be therapeutically effective.[1] However, this system relies heavily on strict adherence to dosing protocols.

5.1 The Fasting Requirement

The mechanism of SNAC is extremely sensitive to the gastric environment.

- **Food Effect:** Presence of food in the stomach stimulates acid secretion (overwhelming the SNAC buffer), increases fluid volume (diluting the SNAC), and physically obstructs the tablet from contacting the mucosa. Studies show that co-administration with food essentially abolishes absorption.[23]
- **Water Volume:** Patients are instructed to take the tablet with no more than 120 mL (4 oz) of water. Increasing water volume to 240 mL significantly reduces bioavailability because it dilutes the local SNAC concentration at the tablet surface.[7]

- **Post-Dose Fasting:** A waiting period of at least 30 minutes is required before eating to allow the tablet to erode and the semaglutide to be absorbed. Extending this wait to 60 minutes or longer can further improve absorption, though 30 minutes is the approved standard.[23]

5.2 Variability and Steady State

Oral absorption of peptides is inherently variable (inter-individual variability). However, the long half-life of semaglutide acts as a buffer against this variability. Daily dosing leads to the accumulation of the drug, smoothing out the peaks and troughs and establishing a stable steady-state concentration that mimics the profile of the weekly injection.[1]

6. Clinical Validation: Non-Inferiority in Weight Loss (The PIONEER Program)

The **PIONEER** clinical development program provided this evidence, specifically through head-to-head comparisons in **PIONEER 4** (vs. Liraglutide) and **PIONEER 10** (vs. Dulaglutide).

6.1 PIONEER 4: Oral Semaglutide vs. Injectable Liraglutide

PIONEER 4 was a randomized, double-blind, double-dummy, phase 3a trial evaluating the efficacy of oral semaglutide 14 mg compared to subcutaneous liraglutide 1.8 mg (Victoza®) and placebo in patients with T2DM.[24]

- **Study Design:** 711 patients were randomized to oral semaglutide 14 mg, subcutaneous liraglutide 1.8 mg (the maximum approved dose for diabetes at the time), or placebo.
- **Weight Loss Outcomes (Week 26):**
  - **Oral Semaglutide 14 mg:** Mean body weight change of **-4.4 kg**.
  - **Liraglutide 1.8 mg:** Mean body weight change of **-3.1 kg**.
  - **Placebo:** Mean body weight change of **-0.5 kg**.
  - **Statistical Result:** Oral semaglutide was statistically **superior** to both placebo ($p < 0.0001$) and injectable liraglutide ($p = 0.0003$) for weight loss.[25]
- **Weight Loss Outcomes (Week 52):**
  - **Oral Semaglutide 14 mg: -5.0 kg**.
  - **Liraglutide 1.8 mg: -3.1 kg**.
  - **Significance:** Superiority was maintained at one year, confirming that the oral formulation delivers durable efficacy exceeding that of the standard daily injectable.[25]

Insight: This trial was pivotal. It proved that the SNAC tablet did not just "match" the injectable; it outperformed the market-leading injectable of that era (Liraglutide) in weight reduction, validating the high bioavailability and potency of the oral formulation.

6.2 PIONEER 10: Oral Semaglutide vs. Injectable Dulaglutide

PIONEER 10 was an open-label, active-controlled trial in Japanese patients comparing oral semaglutide with once-weekly subcutaneous dulaglutide (Trulicity®).[27]

- **Note on Dosage:** The comparator dose was Dulaglutide 0.75 mg, which is the standard approved dose in Japan. This is lower than the 1.5 mg or 3.0/4.5 mg doses used in

Western markets, but valid for the specific regulatory comparison.

- **Weight Loss Outcomes (Week 52):**
  - **Oral Semaglutide 14 mg:** Mean weight loss of **-1.6 kg**.
  - **Dulaglutide 0.75 mg:** Mean weight gain of **+1.0 kg**.
  - **Statistical Result:** The estimated treatment difference (ETD) was **-2.6 kg** in favor of oral semaglutide ($p < 0.0001$).[27]
- **Insight:** While the absolute weight loss numbers were lower in this population (typical for Japanese cohorts with lower baseline BMI), the *relative* performance showed clear superiority of the oral tablet over the weekly injectable competitor.

6.3 PIONEER 2: Oral Semaglutide vs. Oral SGLT2 Inhibitor (Empagliflozin)

Although Empagliflozin is oral, it is a potent weight-loss agent in a different drug class. Comparing them highlights the potency of oral semaglutide.

- **Results (Week 52):** Oral semaglutide 14 mg resulted in **-4.7 kg** weight loss compared to **-3.8 kg** for Empagliflozin 25 mg ($p = 0.0114$).[29] This confirms that oral semaglutide competes favorably even against other mechanisms of weight loss.

6.4 Summary of Weight Loss Efficacy (Table 2)

Study	Population	Oral Semaglutide (14 mg)	Comparator (Injectable/Oral)	Placebo	Statistical Outcome (Weight)
PIONEER 4 [25]	T2D (Global)	**-4.4 kg** (26 wks)	**Liraglutide 1.8 mg (Inj):** -3.1 kg	-0.5 kg	**Superior** to Liraglutide (p=0.0003)
PIONEER 10 [27]	T2D (Japan)	**-1.6 kg** (52 wks)	**Dulaglutide 0.75 mg (Inj):** +1.0 kg	N/A	**Superior** to Dulaglutide (p<0.0001)
PIONEER 2 [29]	T2D (Global)	**-4.7 kg** (52 wks)	**Empagliflozin 25 mg (Oral):** -3.8 kg	N/A	**Superior** to Empagliflozin (p=0.01)

Table 2: Comparative weight loss data from key PIONEER trials utilizing the Trial Product Estimand (assuming treatment adherence).

6.5 PIONEER PLUS: High-Dose Efficacy

Looking beyond the initial approvals, the PIONEER PLUS trial evaluated higher doses of oral semaglutide (25 mg and 50 mg).

- **Results:** At 52 weeks, oral semaglutide 50 mg achieved a mean weight loss of **-8.0 kg**

compared to -4.4 kg for the 14 mg dose.[30]

- **Implication:** This demonstrates that the oral SNAC platform is scalable. Higher doses can be delivered to achieve weight loss magnitudes approaching those of the high-dose injectable Wegovy® (2.4 mg), further cementing the viability of the oral route.

7. Safety, Tolerability, and Future Directions

The safety profile of oral semaglutide across the PIONEER program was consistent with the well-characterized profile of the GLP-1 RA class.

7.1 Gastrointestinal Tolerability

The most common adverse events were gastrointestinal (nausea, vomiting, diarrhea), occurring in 15–20% of patients.[29] Importantly, these effects are largely attributable to the pharmacology of GLP-1 (slowing of gastric emptying) rather than the SNAC excipient. The incidence of nausea was generally similar to that observed with liraglutide and dulaglutide in the head-to-head trials.[25]

7.2 Gastric Mucosal Safety

Given that SNAC works by permeating the gastric membrane and altering local pH, theoretical concerns regarding mucosal damage were rigorously investigated.

- **Reversibility:** Studies utilizing gastroscopy and biomarkers showed that the membrane fluidization caused by SNAC is fully reversible within minutes to hours. No evidence of chronic gastritis, ulceration, or permanent epithelial damage was observed in long-term toxicity studies or clinical trials.[6]
- **SNAC Safety:** SNAC itself is rapidly metabolized and excreted, with no accumulation observed. It has been used safely in other formulations (e.g., Vitamin B12/Eligen B12) and holds GRAS status.[3]

7.3 Recent Developments (2025)

Regulatory documents from 2025 indicate that Novo Nordisk is introducing a new formulation of Rybelsus with *increased* bioavailability. This re-engineered tablet allows for lower milligram doses (e.g., 9 mg bioequivalent to the original 14 mg) to achieve the same plasma exposure.[32] This evolution underscores that the SNAC-tablet platform is not a static technology but an adaptable delivery system capable of optimization to reduce API waste and improve patient convenience.

8. Conclusion

The development of oral semaglutide is a triumph of pharmaceutical engineering that defies the traditional dogma of peptide delivery. The distinction between the tablet and capsule formulations is not merely a matter of preference but a rigid physicochemical necessity driven by the mechanism of the absorption enhancer.

1. **The Tablet Necessity:** SNAC requires a high local concentration to create a transient, buffered, lipophilic microenvironment. The stomach offers the optimal setting for this via tablet erosion, which concentrates the enhancer at the mucosal surface. Enteric-coated capsules fail because they release the drug in the small intestine, where fluid dilution

renders SNAC ineffective and pancreatic proteases (trypsin/chymotrypsin) rapidly destroy the peptide.
2. **Clinical Validation:** The PIONEER clinical trials provide irrefutable evidence that this delivery system works. In PIONEER 4 and PIONEER 10, oral semaglutide demonstrated weight loss efficacy that was not only non-inferior but statistically **superior** to standard doses of injectable liraglutide and dulaglutide.

By transforming the stomach from a hostile barrier into a functional window for absorption, the SNAC-enabled tablet has established a new standard for oral biologics, offering patients the efficacy of an injection with the convenience of a pill.

References

1. A new era for oral peptides: SNAC and the development of oral ..., accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9515042/
2. What is SNAC in oral semaglutide? - Biopharma PEG, accessed on January 1, 2026, https://www.biochempeg.com/article/370.html
3. Oral Bioavailability With SNAC | Biologic Drug Delivery - LGM Pharma, accessed on January 1, 2026, https://lgmpharma.com/blog/oral-bioavailability-biologic-excipient-sourcing/
4. Oral Absorption of Middle-to-Large Molecules and Its Improvement ..., accessed on January 1, 2026, https://www.mdpi.com/1999-4923/16/1/47
5. Development of an orally delivered GLP-1 receptor agonist through ..., accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8602401/
6. The Oral Semaglutide - American Diabetes Association, accessed on January 1, 2026, http://diabetesjournals.org/clinical/article-pdf/42/1/74/744382/diaclincd220118.pdf
7. Relationship Between Oral Semaglutide Tablet Erosion and ... - NIH, accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8251533/
8. Barriers and Strategies for Oral Peptide and Protein Therapeutics ..., accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12030352/
9. Overcoming Oral Peptide Delivery Challenges - Key Strategies, accessed on January 1, 2026, https://seranovo.com/article-3-overcoming-the-hurdles-of-oral-peptide-delivery/
10. Permeation Enhancer-Induced Membrane Defects Assist the Oral ..., accessed on January 1, 2026, https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/6781474d81d2151a029a82d6/original/permeation-enhancer-induced-membrane-defects-assist-the-oral-absorption-of-peptide-drugs.pdf
11. On the Utility of Chemical Strategies to Improve Peptide Gut Stability, accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9059125/
12. 213051Orig1s000 NON-CLINICAL REVIEW(S) - accessdata.fda.gov, accessed on January 1, 2026, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213051Orig1s000PharmR.pdf

13. The Oral Semaglutide Experience - PMC - NIH, accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10788673/
14. Oral Semaglutide: A New GLP-1 Receptor Agonist Product for the ..., accessed on January 1, 2026, https://journalce.powerpak.com/ce/oralsemaglutide-a-new-glp-1
15. Mechanism of absorption of oral semaglutide. SNAC indicates ..., accessed on January 1, 2026, https://www.researchgate.net/figure/Mechanism-of-absorption-of-oral-semaglutide-SNAC-indicates-sodium_fig1_347894668
16. Intestinal Permeation Enhancers for Oral Delivery of Macromolecules, accessed on January 1, 2026, https://www.mdpi.com/1999-4923/11/2/78
17. Application of Permeation Enhancers in Oral Delivery of ... - MDPI, accessed on January 1, 2026, https://www.mdpi.com/1999-4923/11/1/41
18.
19. Oral Semaglutide - PMC - NIH, accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6969659/
20. Relationship Between Oral Semaglutide Tablet Erosion and ..., accessed on January 1, 2026, https://sciencehub.novonordisk.com/scientific-publications/articles/original-article.33750044.relationship-between-oral-semaglutide-tablet.html
21. Impact of sodium caprate dosed as a mini-tablet or suspension on ..., accessed on January 1, 2026, https://www.pharmaexcipients.com/news/sodium-caprate-mini-tablet/
22.
23. A Pharmacological and Clinical Overview of Oral Semaglutide for ..., accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8217049/
24. PIONEER 4 - American College of Cardiology, accessed on January 1, 2026, https://www.acc.org/latest-in-cardiology/clinical-trials/2019/09/20/12/48/pioneer-4
25. Oral semaglutide versus subcutaneous liraglutide and placebo in ..., accessed on January 1, 2026, https://pubmed.ncbi.nlm.nih.gov/31186120/
26. Analysis Shows Oral Semaglutide Beats Empagliflozin for Reducing ..., accessed on January 1, 2026, https://www.ajmc.com/view/analysis-shows-oral-semaglutide-beats-empagliflozin-for-reducing-blood-sugar-offers-more-weight-loss-than-liraglutide
27. Safety and Efficacy of Oral Semaglutide Versus Dulaglutide in ..., accessed on January 1, 2026, https://pubmed.ncbi.nlm.nih.gov/32333876/
28. Effect of Orally Administered Semaglutide Versus Dulaglutide ... - NIH, accessed on January 1, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7846658/
29. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 ..., accessed on January 1, 2026, https://pubmed.ncbi.nlm.nih.gov/31530666/
30. Efficacy and Safety of Once-Daily Oral Semaglutide 25 mg and 50 ..., accessed on January 1, 2026, https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/07/19/15/14/pioneer-plus
31. Oral semaglutide for the treatment of obesity: a retrospective real ..., accessed

on January 1, 2026, https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1593334/full
32. Rybelsus® (oral semaglutide): risk of medication error due to ..., accessed on January 1, 2026, https://assets.publishing.service.gov.uk/media/68dbb351dadf7616351e4c1d/DHPC_Letter-_Rybelsus_2G.pdf
33. PIONEER 6 results show reduced MACE with oral semaglutide in ..., accessed on January 1, 2026, https://www.adameetingnews.org/pioneer-6-results-show-reduced-mace-with-oral-semaglutide-in-type-2-diabetes-patients-with-high-cv-risk/
34. A1C and Weight Results | RYBELSUS® (semaglutide) tablets 7 mg ..., accessed on January 1, 2026, https://www.novomedlink.com/diabetes/products/treatments/rybelsus/efficacy-safety/A1C-and-weight-data.html